Introduction {#sec1}
============

Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin deficiency and insulin resistance. It is associated with a high risk of microvascular, cardiovascular and other complications (such as depression, a mental disorder with unclear pathogenesis) \[[@B1]\]. Most interventions for T2DM are designed to control the blood glucose level. However, these interventions pay little attention to other risk factors and rarely meet the multifaceted needs of patients with T2DM \[[@B5],[@B6]\]. Currently, the main challenges of T2DM treatment include: maintaining tight glycemic control, minimizing the risk of hypoglycemia, controlling cardiovascular risk factors (such as blood pressure and serum lipid concentrations), and reducing or controlling weight. Diabetic patients suffer from a high rate of cardiovascular events. Therefore, the European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes and cardiovascular disease (CVD) emphasize the need for a stringent approach in treating patients with diabetes, suggesting the importance of reducing the cardiovascular events \[[@B7],[@B8]\].

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors (DPP4i) are a pharmacological class of oral hypoglycemic drugs, which could prolong the action of the incretin peptide hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) by inhibiting their breakdown. Previous study suggested that DPP‐4 inhibition might possibly have a beneficial cardiovascular effect in humans \[[@B9]\]. GLP-1 could suppress the release of glucagon from the pancreas. In addition, GLP-1 and GIP could also preserve or enhance β-cell function \[[@B10],[@B11]\]. The levels of intact GLP-1 and GIP could decrease rapidly, due to enzymatic inactivation (mainly DPP-4) and renal clearance \[[@B12]\]. Sitagliptin, a potent and selective DPP4i, is specifically designed to extend the inhibition of DPP-4 enzyme. It could improve glycemic control through enhancing the action of GLP-1and GIP \[[@B13]\]. Fonseca et al. \[[@B14]\] reported that sitagliptin could improve glycemic control and be generally well tolerated by patients with T2DM.

Sitagliptin could better reduce the levels of low-density lipoprotein cholesterol and total cholesterol compared with pioglitazone \[[@B15]\]. Cornel et al. \[[@B16]\] reported that sitagliptin had no clinically significant impact on cardiovascular outcomes. However, whether sitagliptin has clinically significant impact on decreasing cardiovascular events or not is still controversial. Therefore, we conducted this work to assess the cardiovascular risk of sitagliptin in treating patients with T2DM.

Materials and methods {#sec2}
=====================

Study selection {#sec2-1}
---------------

The literature research was conducted using the following scientific and medical databases: international databases (PubMed, Embase, Web of Science and Medline) and Chinese databases (CBM-disc, CNKI), which was up to October 2018. The search terms used were 'sitagliptin', 'diabetes', 'T2DM' and 'type 2 diabetes mellitus'. To avoid omitting relevant articles, no language was imposed, and reference documents listed in the included articles were also researched.

Among the articles identified in the initial research, only those meeting the following criteria were selected for subsequent analysis: (i) patients with T2DM; (ii) compared sitagliptin with placebo or active drugs (oral hypoglycaemic agents and/or insulin) different from other DPP4i; (iii) clinical trials with duration of at least 24 weeks. Potential articles meeting any one of the following criteria were excluded: (i) clinical trials with duration shorter than 24 weeks; (ii) patients with nondiabetic or type 1 diabetic; (iii) reviews, case reports and duplicate reports.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Two authors (De-kang Zeng and Yu-zhi Tang) of the present study served as reviewers to independently verify all potentially suitable clinical trials based on the aforementioned criteria, and extracted data subsequently. Any disagreement was resolved by the third reviewer. For all included articles, results reported in papers were used as the primary source of information. The primary outcome was major cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction (MI) and stroke, and the secondary outcome was all-cause mortality.

Two authors (De-kang Zeng and Yu-zhi Tang) of the present study served as reviewers to independently assess the quality of each eligible study according to the Cochrane Collaboration criteria \[[@B17]\]. Bias risk was determined by: (i) randomization quality, (ii) allocation concealment, (iii) blinding of outcome assessment, (iv) incomplete reporting of outcome data, (v) similarity in baseline clinical characteristics. Studies with three or more bias risks were excluded from the meta-analysis.

Statistical analysis {#sec2-3}
--------------------

This meta-analysis was conducted according to the recommendations of Sacks et al. \[[@B18]\]. Dichotomous data were preferred for clinical reasons. Baseline scores, standard deviations (SDs), and end point means were used to estimate the number of responsive patients under the condition that dichotomous efficacy outcomes were absent \[[@B19]\]. To perform a clinically sound analysis, a worst-case scenario analysis of drop-outs was used, under the assumption that all such patients did not respond to treatment \[[@B20]\]. The weighting of each study was performed according to the number of samples in each study. The meta-regression was used here to examine the impact of moderator variables, such as sex ratio and age, on the study effect size. Statistical analyses were performed using RevMan 5.3 (Cochrane Information Management System) and STATA software 8.0 (Stata Corporation, College Station, TX, U.S.A.). Heterogeneity was assessed using the Q statistic and *I^2^* \[[@B21]\]. A *P*-value \<0.1 or *I^2^* value \>50% indicated that there was significant statistical heterogeneity among the included studies. If there was heterogeneity, the pooled odds ratio (OR) and 95% confidence intervals (CIs) were calculated by Mantel--Haenszel fixed-effects model; otherwise, the random-effects model was used \[[@B22]\]. Finally, funnel plots and Egger's test were used to assess the potential presence of publication bias. This research was performed independently of any funding, as part of the institutional of the investigators.

Results {#sec3}
=======

Selected studies {#sec3-1}
----------------

The literature search yielded 1391 potentially relevant studies. However, only 32 studies met all the inclusion and exclusion criteria mentioned above \[[@B14],[@B15],[@B23]\], and could be used for subsequent analysis ([Figure 1](#F1){ref-type="fig"}). Among these studies, 12 studies were active comparator controlled and 20 studies were placebo controlled. Four studies did not report any adverse events and were excluded from the subsequent analysis. A total of 16082 patients with T2DM were included. Of these, 8536 patients were treated with sitagliptin and the remaining 7546 patients were treated with placebo or active drugs different from other DPP4i. [Table 1](#T1){ref-type="table"} presented the detailed characteristics of the included studies. Figure 1Flow chart of the present study

###### Baseline characteristics of trials included in the meta-analysis

  First author (year)   Sitagliptin   Control   Duration (weeks)                                                                                 
  --------------------- ------------- --------- ------------------ -------------- -------------- ----- ----- ----- -------------- -------------- -----
  Henry (2014)          922           524       398                52.1 ± 8.7     NR             693   388   305   51.5 ± 9.2     NR             54
  Chan (2008)           65            31        34                 68.9 ± 9.8     26.5 ± 4.0     26    16    10    65.3 ± 9.7     26.9 ± 4.9     54
  Ferreia (2013)        211           125       86                 64.8 ± 10.6    26.5 ± 4.8     212   116   96    64.3 ± 9.2     27.0 ± 4.8     54
  Williams (2010)       551           265       286                54.1 ± 9.1     31.2 ± 6.5     540   259   281   54.7 ± 9.9     32.0 ± 6.4     104
  Charbonnel (2006)     464           259       205                54.4 ± 10.4    30.9 ± 5.3     237   141   96    54.7 ± 9.7     31.5 ± 4.9     24
  Raz (2006)            411           214       197                55.4 ± 9.2     31.9 ± 5.3     110   69    41    55.5 ± 10.1    32.5 ± 5.2     44
  Aschner (2006)        488           253       235                54.1 ± 9.8     30.3 ± 5.3     253   130   123   54.3 ± 10.1    30.8 ± 5.5     24
  Reasner (2011)        625           353       272                49.4 ± 10.5    32.9 ± 7.2     621   356   265   50.0 ± 10.5    33.7 ± 7.8     44
  Visboll (2010)        322           157       165                58.3 ± 9.1     31 ± 5         319   169   150   57.2 ± 9.3     31 ± 5         24
  Hermansen (2007)      222           117       105                55.6 ± 9.6     31.2 ± 6.3     219   117   102   56.5 ± 9.6     30.7 ± 6.3     24
  Monteverde (2011)     244           152       92                 50.5 ± 10.9    30.3 ± 5.2     248   148   100   51.7 ± 10.1    29.4 ± 5.2     40
  Dobs (2013)           170           96        74                 54.4 ± 8.8     30.1 ± 6.2     92    55    37    54.8 ± 9.5     30.8 ± 5.6     54
  Pratley (2012)        219           120       99                 55.0 ± 9.0     32.6 ± 5.4     446   228   218   55.4 ± 9.4     32.8 ± 5.1     78
  Arechavaleta (2011)   516           284       232                56.3 ± 9.7     29.7 ± 4.5     519   279   240   56.2 ± 10.1    30.2 ± 4.4     30
  Yang (2012)           197           92        105                54.1 ± 9.0     25.3 ± 3.1     198   108   90    55.1 ± 9.8     25.3 ± 3.6     24
  Bergenstal (2010)     166           86        80                 52 ± 11        32 ± 5         325   168   157   52.5 ± 10      32 ± 5.5       26
  Aschner (2010)        528           217       311                56.3 ± 10.7    30.7 ± 4.7     522   194   328   55.7 ± 10.3    30.9 ± 4.9     24
  Wainstein (2012)      261           143       118                52.4 ± 10.7    30.3 ± 6.1     256   134   122   52.2 ± 11.0    29.6 ± 5.5     32
  Seck (2010)           588           336       252                57.6 ± 8.5     30.9 ± 4.8     584   367   217   57.0 ± 9.1     31.3 ± 5.0     104
  Yoon (2011)           261           137       124                50.2 ± 10.2    29.7 ± 5.1     259   145   114   51.7 ± 11.2    29.6 ± 5.2     24
  Fonseca (2013)        157           97        60                 55.7 ± 8.7     29.9 ± 5.2     156   98    58    56.4 ± 9.4     30.0 ± 5.2     26
  Barzilai (2011)       102           48        54                 71.6 ± 6.1     30.8 ± 5.9     104   49    55    72.1 ± 6.0     31.1 ± 7.2     24
  Yoon (2012)           164           86        78                 51.4 ± 10.0    29.7 ± 4.8     153   90    63    52.3 ± 11.5    29.9 ± 5.3     24
  Raz (2008)            96            49        47                 53.6 ± 9.5     30.4 ± 5.3     94    39    55    56.1 ± 9.5     30.1 ± 4.4     30
  Rosenstock (2006)     175           93        82                 55.6 ± 10.4    32.0 ± 5.2     178   103   75    56.9 ± 11.1    31.0 ± 5.0     24
  Stein (2014)          10            6         4                  61.3 ± 8.2     34.3 ± 3.3     11    8     3     60.8 ± 7.6     32.7 ± 2.7     48
  Zang (2016)           184           117       67                 51.4 ± 11.0    27.2 ± 4.0     183   102   81    51.7 ± 10.7    27.3 ± 3.4     26
  Kim (2017)            147           81        66                 54.8 ± 8.5     25.2 ± 2.7     145   84    61    53.1 ± 9.2     25.0 ± 2.8     30
  Ji (2016)             120           74        46                 51.7 ± 10.2    26.0 ± 3.5     126   69    57    52.6 ± 9.5     26.0 ± 3.7     24
  Ba (2016)             249           117       132                57.5 ± 9.5     25.4 ± 3.2     249   132   117   56.5 ± 9.3     25.3 ± 3.2     24
  Shankar (2016)        234           130       104                58.6 ± 8.4     25.9 ± 3.0     233   116   117   56.7 ± 9.1     26.1 ± 2.9     24
  Duan (2016)           105           59        46                 50.32 ± 3.21   27.10 ± 1.73   103   55    48    48.88 ± 2.91   27.32 ± 1.81   24

Abbreviations: BMI, body mass index; *n*, number; NR, not available.

MACEs {#sec3-2}
-----

MACEs were reported in 28 studies. In these clinical trials, 86 of 8536 patients receiving sitagliptin and 82 of 7546 comparator patients reported MACE, respectively. The pooled OR was 0.85 (95% CI = 0.63--1.15, z = 1.04, *P* 0.30), indicating that there was no statistical difference between those two groups on the incidence of MACE. The risk of MACE was not significantly increased in patients receiving sitafliptin ([Figure 2](#F2){ref-type="fig"}A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias ([Figure 2](#F2){ref-type="fig"}B). Meanwhile, the results of Egger's test (*P*=0.54) also showed that the outcome was not influenced by the potential publication bias. Meanwhile, the results of meta-regression showed that our effect size was not influenced by these moderator variables.

![Number of patients with MACEs in two groups\
(**A**) Meta-analysis showed the non-significant difference on this outcome; (**B**) funnel plots showed no potential publication bias.](bsr-39-bsr20190980-g2){#F2}

The study period of two included studies was 104 weeks. Therefore, the sensitivity analysis was conducted by excluding these two studies. The new pooled OR was 0.89 (95% CI = 0.65--1.23, z = 0.69, *P*=0.49), which was similar to the original results. Meanwhile, the subgroup analysis was conducted according to the study period (≥54 and \<54 weeks). The pooled OR of these studies with study period ≥54 weeks was 1.16 (95% CI = 0.69--1.96, z = 0.57, *P*=0.57), and the pooled OR of these studies with study period \<54 weeks was 0.73 (95% CI = 0.50--1.05, z = 1.69, *P*=0.09). These results indicated that our conclusion was not significantly influenced by the different treatment periods. The subgroup analysis was also conducted according to the different sorts of control groups (sitagliptin vs. placebo and sitagliptin vs. active drugs). The pooled OR of sitagliptin vs. placebo was 0.73 (95% CI = 0.49--1.09, z = 1.55, *P*=0.12), and the pooled OR of sitagliptin vs. active drugs was 1.05 (95% CI = 0.66--1.68, z = 0.22, *P*=0.83). These results indicated that our conclusion was not significantly influenced by the different sorts of control groups.

MI {#sec3-3}
--

MI was reported in 16 studies. In these clinical trials, 19 of 6073 patients receiving sitagliptin and 22 of 4935 comparator patients reported MI, respectively. The pooled OR was 0.66 (95% CI = 0.38--1.16, z = 1.44, *P*=0.15), indicating that there was no statistical difference between those two groups on the incidence of MI. The risk of MI was not significantly increased in patients receiving sitafliptin ([Figure 3](#F3){ref-type="fig"}A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias ([Figure 3](#F3){ref-type="fig"}B). Meanwhile, the results of Egger's test (*P*=0.47) also showed that the outcome was not influenced by the potential publication bias.

![Number of patients with MI in two groups\
(**A**) Meta-analysis showed the non-significant difference on this outcome; (**B**) funnel plots showed no potential publication bias.](bsr-39-bsr20190980-g3){#F3}

Stroke {#sec3-4}
------

Stroke was reported in 16 studies. In these clinical trials, 15 of 5329 patients receiving sitagliptin and 14 of 4421 comparator patients reported stroke, respectively. The pooled OR was 0.83 (95% CI = 0.44--1.54, z = 0.59, *P*=0.55), indicating that there was no statistical difference between those two groups on the incidence of stroke. The risk of stroke was not significantly increased in patients receiving sitafliptin ([Figure 4](#F4){ref-type="fig"}A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias ([Figure 4](#F4){ref-type="fig"}B). Meanwhile, the results of Egger's test (*P*=0.26) also showed that the outcome was not influenced by the potential publication bias.

![Number of patients with stroke in two groups\
(**A**) Meta-analysis showed the non-significant difference on this outcome; (**B**) funnel plots showed no potential publication bias.](bsr-39-bsr20190980-g4){#F4}

Mortality {#sec3-5}
---------

There were eight studies reported information on mortality (either cardiovascular death or others). In these clinical trials, 12 of 2659 patients receiving sitagliptin and 19 of 2375 comparator patients experienced death, respectively. The pooled OR was 0.52 (95% CI = 0.26--1.07, z = 1.78, *P*=0.07), indicating that there was no statistical difference between those two groups on the incidence of mortality. The risk of mortality was not significantly increased in patients receiving sitafliptin ([Figure 5](#F5){ref-type="fig"}A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias ([Figure 5](#F5){ref-type="fig"}B). Meanwhile, the results of Egger's test (*P*=0.30) also showed that the outcome was not influenced by the potential publication bias.

![Number of mortality in two groups\
(**A**) Meta-analysis showed the non-significant difference on this outcome; (**B**) funnel plots showed no potential publication bias.](bsr-39-bsr20190980-g5){#F5}

Discussion {#sec4}
==========

With more than 300 million patients with T2DM in the whole world, as drugs for T2DM, it is not only important to manage the blood glucose but also control the risk of complications, especially decreasing cardiovascular risk \[[@B53],[@B54]\]. So the analysis of serious adverse events in clinical trials is essential for assessing the safety profile of newer drugs. Sitagliptin, as a representative drug of DPP4i, is usually used for treating T2DM. By slowing incretin degradation, DPP4i enhance meal-stimulated active GLP-1 and GIP levels by two- to threefold. When the blood glucose concentration is elevated, GLP-1 and GIP can increase the pancreatic β-cell synthesis and release insulin by increasing intracellular signaling pathways. Sitagliptin could be able to increase the concentration of GLP-1 and GIP \[[@B13]\].

Previous study suggested that sitagliptin could play a role in modifying the high risk of fatal arrhythmias that are inherent in T2DM \[[@B55]\]. However, the efficacy of sitagliptin for T2DM complications remains uncertain. Previous pooled analyses of individual compounds have yielded discordant results, with incidence of cardiovascular events either reduced or unchanged \[[@B56],[@B57]\]. Our results found that the use of sitagliptin would not increase the risk of MACE compared with placebo or other hypoglycemic drugs. The strength of this conclusion was the large number of trials with a large number of patients, and the present meta-analysis confirmed the trend reported in the previous study \[[@B57]\]. We also found that the incidences of MI and stroke were not significantly increased in patients receiving sitagliptin.

Sitagliptin is mostly excreted as unchanged drug by kidney; then, the renal insufficiency would increase the circulating levels of sitagliptin \[[@B58]\]. In contrast, vildagliptin is primarily metabolized by hydrolysis to an inactive compound; then, only approximately 20% of vildagliptin is excreted unchanged \[[@B59]\]. In addition, saxagliptin is mainly metabolized by liver to an active compound; then itself and its metabolites are renally excreted \[[@B60]\]. Many studies have shown that sitagliptin and vildagliptin were comparable on safety and tolerability, both in short-term and long-term treatments \[[@B61],[@B62]\]. Although experience with saxagliptin is more limited, some studies also reported that this drug was tolerable and safe \[[@B60],[@B63]\].

Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for treating diabetes. Nowadays, six kinds of SGLT2 (tofogliflozin, canagliflozin, empagliflozin, dapagliflozin, ipragliflozin, and luseogliflozin) for diabetes are approved. The common adverse events of SGLT2 include: reproductive system infection, urinary system infection, and ketoacidosis \[[@B64]\]. The common adverse event of sitagliptin is gastrointestinal reaction (such as abdominal pain, diarrhea, nausea, vomiting). As the second- and third-line medication for T2DM, SGLT2 can be used in combination with metformin or other hypoglycemic agents.

The main limitation of the present study was that the dosage of sitagliptin in each study was not the same, which might influence the results of this meta-analysis. However, this limitation was also the general problem for meta-studies to solve. Meanwhile, the main purpose of the existing studies about sitagliptin was to assess the efficacy, tolerability, and safety of blood glucose control. The final conclusion about the influence of sitagliptin on cardiovascular risk in T2DM patients still needs future studies to further investigate, especially the large-scale clinical trials. Finally, a double-blind, controlled, randomized, multi-center study would be needed to highlight the usefulness of sitagliptin and other gliptins. In conclusion, available data from these short- and medium-term trials showed that treatment with sitagliptin did not increase the risk of cardiovascular events in patients with T2DM.
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